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A systematic SNP selection 
approach to identify mechanisms 
underlying disease aetiology: 
linking height to post-menopausal 
breast and colorectal cancer risk
Rachel J. J. Elands1, Colinda C. J. M. Simons1, Mona Riemenschneider2,3, Aaron Isaacs4,5, 
Leo J. Schouten1, Bas A. Verhage1, Kristel Van Steen6, Roger W. L. Godschalk7,  
Piet A. van den Brandt1, Monika Stoll2,5 & Matty P. Weijenberg1
Data from GWAS suggest that SNPs associated with complex diseases or traits tend to co-segregate in 
regions of low recombination, harbouring functionally linked gene clusters. This phenomenon allows for 
selecting a limited number of SNPs from GWAS repositories for large-scale studies investigating shared 
mechanisms between diseases. For example, we were interested in shared mechanisms between adult-
attained height and post-menopausal breast cancer (BC) and colorectal cancer (CRC) risk, because 
height is a risk factor for these cancers, though likely not a causal factor. Using SNPs from public GWAS 
repositories at p-values < 1 × 10−5 and a genomic sliding window of 1 mega base pair, we identified 
SNP clusters including at least one SNP associated with height and one SNP associated with either 
post-menopausal BC or CRC risk (or both). SNPs were annotated to genes using HapMap and GRAIL and 
analysed for significantly overrepresented pathways using ConsensuspathDB. Twelve clusters including 
56 SNPs annotated to 26 genes were prioritised because these included at least one height- and one BC 
risk- or CRC risk-associated SNP annotated to the same gene. Annotated genes were involved in Indian 
hedgehog signalling (p-value = 7.78 × 10−7) and several cancer site-specific pathways. This systematic 
approach identified a limited number of clustered SNPs, which pinpoint potential shared mechanisms 
linking together the complex phenotypes height, post-menopausal BC and CRC.
Knowledge on single nucleotide polymorphisms (SNPs) and gene-environment interactions associated with 
complex diseases provides insights into underlying etiologic mechanisms1,2. Genome-wide gene-environment 
interaction studies have typically been applying two-step approaches that are aimed at increasing power. Two-step 
genome-wide gene-environment interaction studies often utilise a SNP reduction step, in which the number of 
SNPs to include in the analysis is reduced3. The SNPs are subsequently tested for interaction, limiting multiple 
testing. However, for large-scale epidemiological studies with exhaustive bio-samples from which DNA is not 
immediately suitable for genome-wide platforms, e.g. DNA from nails, the only option is platforms allowing 
genotyping of a limited number of SNPs. For example, we have previously genotyped toenail DNA using the 
Agena BioscienceTM MassARRAY® platform, which allows genotyping of a maximum of 40 SNPs at once in 
1Department of Epidemiology, GROW–School for Oncology and Developmental Biology, Maastricht University, 
Maastricht, the Netherlands. 2Institute of Human Genetics, Genetic Epidemiology, University of Münster, Münster, 
Germany. 3Department of Bioinformatics, Straubing Center of Science, Straubing, Germany. 4Department of 
Epidemiology, Genetic Epidemiology Unit, Erasmus Medical Center, Rotterdam, the Netherlands. 5Department 
of Biochemistry, Maastricht Centre for Systems Biology (MaCSBio), CARIM–School for Cardiovascular Diseases, 
Maastricht University, Maastricht, the Netherlands. 6Department of Electrical Engineering and Computer 
Science, Montefiore Institute, University of Liège, Liège, Belgium. 7Department of Pharmacology and Toxicology, 
NUTRIM–School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the 
Netherlands. Correspondence and requests for materials should be addressed to R.J.J.E. (email: rachel.elands@
maastrichtuniversity.nl)
Received: 29 October 2015
Accepted: 15 December 2016
Published: 24 January 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:41034 | DOI: 10.1038/srep41034
large-scale epidemiologic studies4. Therefore, an alternative systematic strategy is needed to reduce the number 
of relevant SNPs for studying disease aetiology through, for example, gene-environment interactions. Data from 
genome-wide association studies (GWAS) suggest that SNPs associated with complex diseases or traits are not 
randomly distributed across the genome but tend to co-segregate in regions of low recombination, harbouring 
functionally linked gene clusters5. Such an enrichment of loci associated with complex traits or diseases has been 
observed throughout the human genome5 and offers an opportunity to SNP reduction.
Approaches for gene-environment interaction studies differ according to study objective. Searching for 
genetic causes of disease is nowadays generally an agnostic approach. In gene-environment-wide interaction 
studies, the starting point is also typically the genetic variation and how its interaction with the environment 
can contribute to the missing heritability6. Alternatively, studies aimed at understanding how the environment 
is associated with cancer risk are generally performed via a hypothesis-driven approach where the starting point 
is the environmental factor and the genetic variation is a time-independent biomarker of pathway involvement2. 
We were interested in the association between adult-attained height and cancer risk. Adult-attained height is 
an established risk factor for cancer risk at several sites; the most convincing evidence has been reported for 
post-menopausal breast cancer and colorectal cancer risk7,8. For every 5 cm increase in height, post-menopausal 
breast cancer risk is reported to be increased by 7 to 11%7,9,10 and colorectal cancer risk is increased by 6 to 11% 
in women and 4 to 9% in men8,10,11. Adult-attained height in itself is probably not causally related to cancer, but 
rather a consistent marker for shared mechanisms determining both height and cancer risk, e.g. growth processes, 
which are influenced by factors such as growth promoting hormones and energy balance in early life12. Height 
is determined in the first 20 years of life by aggregated genetic13 and environmental components12, which deter-
mine linear growth but may also spur neoplastic growth later in life. Although adult-attained height may not be a 
target for intervention to reduce cancer risk, understanding how height is associated with cancer risk is essential 
to expand our knowledge concerning the pathways that lead to cancer development later in life. To study shared 
mechanisms between height and post-menopausal breast and colorectal cancer risk, we have applied a systematic 
SNP reduction strategy based on existing GWAS repositories and based on the fact that SNPs associated with 
complex diseases or traits tend to co-segregate in regions of low recombination. This knowledge was taken for-
ward and we sought for clusters that included both height- and either postmenopausal breast cancer- or colorectal 
cancer-associated SNPs (or both) by comprehensively overlaying GWAS for these endpoints.
Methods
Search strategy. SNPs from the publically available manually curated National Human Genome Research 
Institute (NHGRI) Catalog of published GWAS14 and the Johnson and O’Donnell database15 associated with 
either height, post-menopausal breast or colorectal cancer risk were selected if these had a p-value < 1 × 10−5, a 
minor allele frequency (MAF) ≥ 1% in Caucasians, and were added to the catalogues up to June, 2014. Selected 
SNPs also included SNPs from meta-analyses on GWAS, which may have included SNPs with a p-value < 1 × 10−5 
that did not reach this threshold in individual GWAS. The p-value cut-off for the selection of SNPs is a rather 
liberal value given the focus on genetic variation that tags mechanisms important for the multiple phenotypes 
of interest, in this case, height, post-menopausal breast cancer and colorectal cancer. Therefore, allowing a lib-
eral p-value threshold permits one to identify clustered GWAS SNPs for a combination of different traits or 
diseases rather than clustered GWAS SNPs for a single phenotype. Genome-wide significant common variants 
(p-value < 5 × 10−8) and common variants that do not reach this criterion explain substantially large amounts 
of the heritability of complex traits and complex diseases; because SNPs below genome-wide significance 
(p-value > 5 × 10−8) with marginal individual effect sizes may likely interact with other common SNPs and envi-
ronmental components16,17. SNPs identified in non-Caucasian populations were included if the corresponding 
MAF was ≥ 1% in Caucasians, for the reason that SNP-phenotype associations from different ancestries in inde-
pendent GWAS might be informative to single out regions that link height to cancer risk. Including these SNPs 
from GWAS with other ancestries will also make our selection more comprehensive given that a number of SNPs 
may not yet have been explored in populations from Caucasian ancestry as a consequence of low signal resolution 
in older GWAS or because of differences in SNP coverage across genotyping platforms.
Clustering methodology. Our clustering methodology was based on the assumption that GWAS SNPs 
associated with complex diseases or traits are not randomly distributed across the genome but tend to clus-
ter in regions of low recombination5. Using a sliding window of 1 megabase pair (Mbp), genomic regions 
including at least one SNP from GWAS associated with height and one SNP from GWAS associated with either 
post-menopausal breast or colorectal cancer risk (or both) located within were designated as a SNP cluster. SNPs 
were clustered from the first height- or cancer risk-associated SNP that was identified from GWAS until no addi-
tional SNPs within the genomic sliding window of 1 Mbp could be found (Fig. 1). Each cluster was assigned a 
unique cluster ID. The reason for implementing a relatively wide-ranging genomic sliding window (1 Mbp) was to 
allow for a sufficient number of SNPs, associated with multiple phenotypes, to cluster in regions of low recombi-
nation. We experimentally tested more conservative genomic sliding windows (0.1, 0.2, 0.3, and 0.5 Mbp), which 
resulted in identifying clusters with height- and breast cancer risk- or colorectal cancer risk-associated SNPs, but 
SNPs annotated to the same gene were not always in the same cluster anymore (which particularly affected large 
clusters with multiple SNPs annotated to the same gene). Furthermore, a few clusters were no longer identified. 
A wide-ranging genomic sliding window is preferable because the majority of GWAS SNPs reside in non-coding 
regions, potentially marking long-ranging disease-associated areas rather than pointing to individual genes. For 
example, 40.8% of SNPs from GWAS in DNAse I hypersensitive sites can be linked to target promotors over dis-
tances longer than 250 Kbp18.
SNPs from the clusters were geographically mapped to a gene according to HapMap release 37 and annotated 
to a gene according to “Gene Relationships Among Implicated Loci” (GRAIL) (https://www.broadinstitute.org/
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mpg/grail/). GRAIL accounts for the three-dimensional structure of the DNA, resulting in functional annota-
tions. SNP clusters were prioritised when these contained at least one height-associated SNP and one cancer 
risk-associated SNP that were mapped to the same gene according to the HapMap or GRAIL annotation (or both, 
allowing that HapMap and GRAIL may yield different annotations) or a combination of HapMap and GRAIL 
annotations. For each SNP in the prioritised set of clusters, the rs-number, mapped gene, publication informa-
tion, SNP-phenotype information, the significance of the association, the effect size or beta-coefficient, confi-
dence interval, ancestry and the risk allele (reported in the catalogues and from Ensembl (http://www.ensembl.
org)) were collected. Within a cluster, pair-wise linkage disequilibrium (LD) was examined using SNAP version 
2.2, (https://www.broadinstitute.org/mpg/snap/). Two or more SNPs in high pair-wise LD, i.e. r2 > 0.7, marked 
redundant information within the cluster. Within LD pairs, SNPs with the lowest evidence for regulatory func-
tion annotation were excluded, but only if the cluster criteria were not violated. Ensembl genome browser was 
used to determine the genomic region of the SNPs and to identify whether these were localised in a regulatory 
region19. Regulatory functional annotation of SNPs was evaluated using a ranking ranging from 1–6 provided by 
RegulomeDB (http://www.regulomedb.org/)20. The ranking is based on the overlap of existing functional data 
including annotation to cis-expression quantitative trait loci (cis-eQTLs) and evidence for protein/transcription 
factor binding. SNPs that were likely linked to the expression of a gene target (cis-eQTLs) were assigned the high-
est possible ranking, i.e. scores 1a-1f, in RegulomeDB. SNPs that likely only affected protein binding were ranked 
lower (scores 2–3) and SNPs, for which there was minimal binding evidence (rank 4–6) or for which no evidence 
was available (score 0) were assigned the lowest evidence for regulatory function in RegulomeDB. The rationale to 
prioritise SNPs on the basis of regulatory information was derived from the knowledge that a significant number 
of SNPs associated with quantitative traits and common diseases in GWAS are concentrated in non-coding reg-
ulatory DNA sequences, therefore it is likely that regulatory processes underlie the relation between a SNP from 
GWAS and a phenotype18,21.
Biological interpretation: gene set over-representation analyses. The gene annotations for the 
different SNPs in the resulting prioritised set of clusters, were imported to ConsensusPathDB (http://consensus-
pathdb.org/)22 to conduct gene set over-representation analyses. In these analyses, pathways and gene ontology 
(GO) categories were tested for over-representation in the uploaded gene set. We primarily based these analyses 
on functional annotations from GRAIL. Tests were based on the hypergeometric test with a p-value cutoff set to 
0.01. Multiple testing was accounted for and the q-value threshold was set at 0.05. Pathway over-representation 
Figure 1. Flow diagram with overview of SNP selection methodology and the corresponding results. 
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analyses and GO-over-representation analyses were performed for all clusters combined as well as separately for 
clusters including height- and post-menopausal breast cancer risk-associated SNPs and clusters including height- 
and colorectal cancer risk-associated SNPs.
Results
An overview of the selection steps and the corresponding output is shown in Fig. 1. The NHGRI Catalog included 
1751 curated publications with 11,912 SNPs and the Johnson and O’ Donnell database contained 56,411 SNPs 
from 118 articles. After selecting SNPs on the basis of the p-value (p < 1 × 10−5) and MAF (≥ 1% in Caucasians) 
and filtering out duplicates, due to multiple associations in GWAS, we started clustering with 721 SNPs from 
both GWAS repositories. 514 SNPs were associated with height, 157 SNPs were associated with post-menopausal 
breast cancer risk and 50 SNPs were associated with colorectal cancer risk. None of the individual SNPs were 
associated with multiple phenotypes, i.e. height, post-menopausal breast cancer risk and/or colorectal cancer 
risk. Using the clustering method with a genomic sliding window of 1 Mbp, 40 clusters containing altogether 161 
SNPs annotated to 97 genes on the basis of HapMap and 89 genes on the basis of GRAIL (9 SNPs could not be 
annotated) were formed, each including at least one SNP associated with height and one SNP associated either 
with post-menopausal breast or colorectal cancer risk (see Table S1). No SNP clusters were identified with com-
binations of SNPs that were associated with height, and both post-menopausal breast and colorectal cancer risk.
Twelve clusters containing altogether 56 SNPs, annotated to a total of 29 genes in HapMap and 26 genes 
in GRAIL (five SNPs could not be annotated), were prioritised as these clusters contained at least one 
height-associated SNP and one cancer risk-associated SNP that were annotated to the same gene. HapMap 
and GRAIL SNP-gene annotations were the same for 64.7% of the cases where both annotations were available 
(n = 51). Characteristics of the SNPs in the 12 prioritised SNP clusters are shown in Tables 1 and S1. Eight SNPs 
in five of the prioritised clusters were eliminated from the total of 56 SNPs, leading to 48 SNPs in the prioritised 
clusters, due to the fact that these SNPs were in high LD (r2 > 0.7) with another SNP in the same cluster, there-
fore these SNPs were likely to tag redundant information. Of the 12 prioritised clusters, 8 clusters included 19 
height- and 14 post-menopausal breast cancer risk-associated SNPs and four clusters included 10 height- and 
five colorectal cancer-risk associated SNPs. Of the 33 SNPs in height-breast cancer clusters, 26 SNPs were anno-
tated to the same gene in sets of two or more height- and breast cancer risk-associated SNPs, leading to 9 gene 
annotations: ID4, ZMIZ1, MCHR1 (in GRAIL)/MKL1 (in HapMap), ESR1, RAD51B, TNS1, TNP1, TET2 and 
FAM46A. Of the 15 SNPs in height-colorectal cancer clusters, 8 SNPs were annotated to the same gene in pairs of 
height- and colorectal cancer-risk associated SNPs, leading to the following four gene annotations: BMP2, PITX1, 
DCBLD1 and BARX1. One prioritised cluster, cluster ID 22, contained two genes, i.e. TNS1 and TNP1, to which 
height- and breast cancer risk-associated SNPs were annotated that were found associated in independent GWAS.
Annotation of genomic region and regulatory function. According to Ensembl genome browser the 
majority of candidate SNPs (n = 48) are located in introns (n = 25) and in intergenic regions (n = 17) (Table 1). 
The remaining SNPs were located in an enhancer (n = 3), upstream of a gene (n = 3), the promotor (n = 3), an 
exon (n = 3), or the promotor flanking region (n = 1) (Table 1). According to RegulomeDB, 27 SNPs may affect 
transcription factor binding (score 1–5), of which five also affect the expression of a gene target, termed cis-eQTLs 
(score 1a–1f), and thus these had the highest regulatory evidence (Table 1).
Pathway over-representation analyses. Pathway over-representation analysis based on the 26 gene 
annotations from GRAIL indicated the Indian hedgehog (Ihh) signalling pathway as the most significant overrep-
resented pathway (p-value = 7.78 × 10−7) (based on the following genes: BMP2, STK36, IHH, PTCH1) (Table 2). 
Pathways that followed were ligand-receptor interactions (IHH, PTCH1) (p-value = 5.76 × 10−5) and signalling 
in basal cell carcinoma (BMP2, STK36, PTCH1) (p-value = 6.73 × 10−5) (Table 2). For comparison, when using 
the 29 HapMap gene annotations, the most significant overrepresented pathways were the Ihh signalling pathway, 
signalling in basal cell carcinoma, and the Transforming Growth Factor-beta (TGF-β)  signalling pathway (data 
not shown).
A separate pathway over-representation analysis for genes annotated to SNPs that were associated with height 
or post-menopausal breast cancer risk also retrieved the Ihh pathway as the most overrepresented pathway 
(STK36, IHH) (p-value = 1.13 × 10−4), as well as some distinct pathways, such as the ERBB4 signalling pathway 
(ESR1, TNRC6B) (p-value = 9.10 × 10−3) and androgen receptor pathway (ESR1, ZMIZ1) (p-value = 9.02 × 10−3) 
(Table 2). A separate pathway over-representation analysis for genes from clusters that contained SNPs asso-
ciated with height or colorectal cancer risk, indicated that the Ihh signalling pathway (BMP2, PTCH1) 
(p-value = 2.81 × 10−4) and signalling in basal cell carcinoma (BMP2, PTCH1) (p-value = 2.53 × 10−4) (Table 2) 
were overrepresented.
Gene ontology over-representation analyses. A gene ontology term over-representation analy-
sis, based on the 26 gene annotations from GRAIL, indicated the following top three most significantly over-
represented gene ontology terms for molecular and biological processes: regulation of biosynthetic process 
(p-value = 4.85 × 10−6), regulation of macromolecule metabolic process (p-value = 2.85 × 10−5) and epithelial 
cell proliferation (p-value = 3.29 × 10−5) (Table 3).
Discussion
We present a systematic approach for epidemiologic studies to prioritise SNPs associated with multiple complex 
diseases or traits using all GWAS repository data publically available to elucidate aetiologic pathways. The cluster-
ing methodology in this approach relies on the assumption that SNPs from GWAS found associated with complex 
diseases or traits are not randomly distributed across the genome, but tend to cluster in regions of low recom-
bination5. This allows for a systematic narrowing down of the genomic search field and we were able to identify 
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PathwayjSNP IDa Phenotypeb Scored Cis-eQTLe
Transcripition factor 
bindingf #1 #2 #3
Cluster 
ID 22 rs13387042 BC intergenic 2q 0 0 TNP1 TNP1 ✓ ✓
rs2553026 H enhancer 0 0 TNP1 NA
rs1351164 H intron 0 0 TNS1 NA
rs16857609 BC intron 0 5 TNS1 NA
rs6435999 H intron 0 0 TNS1 DIRC3
rs3791950 H intergenic 0 2b RUNX3, PAX5, TAF1 TNS1 TNS1
rs10187066 H intron 0 1 f SLC11A1, CYP27A1 ZNF142 STK36
Hedgehog 
signalling
rs12470505* a H upstream gene 1 1 f SLC23A3 USF1 CCDC108 IHH ✓ ✓ ✓ Hedgehog signalling
rs1052483* H exon 1 1 f SLC23A3 NHEJ1 IHH ✓ ✓ ✓ Hedgehog signalling
rs6724465* H intron 1 1 f SLC23A3 SLC23A3 IHH ✓ ✓ ✓ Hedgehog signalling
rs16859517 H intergenic 0 5 SLC23A3 IHH ✓ ✓ ✓ Hedgehog signalling
Cluster 
ID 27 rs9790517 BC intron 4q 0 0 TET2 TET2 ✓ ✓
rs10010325 H intron 0 0 TET2 TET2 ✓ ✓
rs6855629 H intron 0 6 TET2 EEF1AL7
Cluster 
ID 29 rs526896* 
a H intergenic 5q 1 5 PITX1 PITX1 ✓ ✓
rs31198* H intron 1 5 PITX1 PITX1 ✓ ✓
rs647161 CRC intron 0 5 PITX1 PITX1 ✓ ✓
Cluster 
ID 32 rs1047014 H upstream gene 6p 0 5 ID4 ID4 ✓ ✓
rs16882214 BC intergenic 0 0 ID4 NA
Cluster 
ID 33 rs2322633 H intron 6q 0 6 BCKDHB BCKDHB
rs310405 H intergenic 0 0 FAM46A NA
rs17530068 BC intergenic 0 0 FAM46A FAM46A
Cluster 
ID 34 rs961764 H intergenic 6q 0 0 VGLL2 RFXDC1
rs2057314 CRC intron 0 4 POLR2A, SPI1, TCF7L2, TCF12, NFIC, FOS DCBLD1 DCBLD1
rs9285425 H intron 0 5 DCBLD1 DCBLD1
Cluster 
ID 7 rs3757318* 
a BC intron 6q 1 2c HNF4A, HNF4G C6orf97 C6orf97
rs3734805* BC 3 prime UTR variant 1 0 C6orf97 C6orf97
rs2046210 BC intergenic 0 1 f C6orf97 ESR1 C6orf97
rs9383938 BC intron 0 5 RFX3 ESR1 C6orf97
rs543650 H intron 0 0 ESR1 ESR1 ✓ ✓ ✓
rs9383951 BC intergenic 0 4 GATA2, SETDB1 ESR1 ESR1 ✓ ✓ ✓
rs2982712 H intron 0 0 ESR1 ESR1 ✓ ✓ ✓
Cluster 
ID 39 rs10114408 CRC intergenic 9q 0 6 BARX1 BARX1 ✓ ✓
rs1257763 H intergenic 0 0 PTPDC1 BARX1 ✓ ✓
rs16910061 H upstream gene 0 5 JUND FBP2 FBP1 ✓ ✓
rs473902 H intron 0 3a POL2RA PTCH1 PTCH1 ✓ ✓ ✓ Hedgehog signalling
rs10512248 H promotor 0 6 PTCH1 PTCH1 ✓ ✓ ✓ Hedgehog signalling
rs2025151 H enhancer 0 1 f HABP4 POL2RA, RUNX3 ZNF367 HABP4 ✓ ✓
rs10816533 H promotor 0 1 f LOC642921 ZNF510 ZNF782 ✓ ✓
Cluster 
ID 5 rs704010 BC intron 10q 0 2b POLR2A, SPI1, CTCF ZMIZ1 ZMIZ1 ✓ ✓
rs7916441* a H enhancer 1 5 GABPB1 ZMIZ1 ZMIZ1 ✓ ✓
rs780151* H intron 1 5 ZMIZ1 ZMIZ1 ✓ ✓
rs12355688 BC exon 0 4 USF1, USF2 ZMIZ1 ZMIZ1 ✓ ✓
rs2145998* H intergenic 1 5 PPIF ZMIZ1 ✓ ✓
Continued
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clusters that were of relevance to the height-cancer association. Twelve clusters were identified that contained at 
least one height- and one cancer risk-associated SNP annotated to the same gene. Height- and post-menopausal 
breast cancer risk-associated SNPs (n = 33) clustered together in 8 clusters. In these, 26 SNPs were annotated to 
the same gene in sets of two or more height- and breast cancer risk-associated SNPs, leading to the following 9 
gene annotations: ID4, ZMIZ1, MCHR1 (in GRAIL)/MKL1 (in HapMap), ESR1, RAD51B, TNS1, TNP1, TET2 
and FAM46A. Height- and colorectal cancer risk-associated SNPs (n = 15) clustered together in four clusters. In 
these, 8 SNPs were annotated to the same gene in pairs of height- and colorectal cancer risk-associated SNPs, 
leading to the following four gene annotations: BMP2, PITX1, DCBLD1, and BARX1.
The SNP selection strategy proposed here can typically be used to identify shared mechanisms between mul-
tiple traits or diseases, using gene-environment interactions for example. A number of two-step methods have 
been developed based on genome-wide data prioritising relevant SNPs within the own study population and 
subsequently testing these SNPs for interactions3,6. These existing strategies prioritise SNPs related to exposure 
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PathwayjSNP IDa Phenotypeb Scored Cis-eQTLe
Transcripition factor 
bindingf #1 #2 #3
rs941873 * a H promoter flanking 1 4 HSF1, MAZ ZCCHC24 ZMIZ1 ✓ ✓
Cluster 
ID 15 rs2588809 BC intron 14q 0 0 RAD51B RAD51B
rs1570106 H intron 0 0 RAD51B RAD51B
rs999737 BC intron 0 6 RAD51B RAD51B
Cluster 
ID 23 rs961253 CRC intergenic 20p 0 5 FERMT1 FERMT1 ✓
rs967417* H intergenic 1 6 BMP2 BMP2 ✓ ✓ ✓ Hedgehog signalling
rs2145270* H intergenic 1 0 BMP2 BMP2 ✓ ✓ ✓ Hedgehog signalling
rs2145272* a H intergenic 1 3a STAT3, BCL11A, NFKB1, CHD2, EP300, IKZF1 BMP2 BMP2 ✓ ✓ ✓
Hedgehog 
signalling
rs4813802 CRC promotor 0 3a
STAT3, CHD2, SETDB1, 
USF2, HNF4A, JUND, 
JUN, FOS, TRIM28, 
BACH1, TFAP2A, 
TFAP2C
BMP2 BMP2 ✓ ✓ ✓ Hedgehog signalling
Cluster 
ID 25 rs139909 H intron 22q 0 2b
RUNX3, BATF, FOXM1, 
NFIC, ATF2, MTA3 TNRC6B TNRC6B ✓ ✓
rs5757949 H intron 0 5 MKL1 MCHR1
rs6001930 BC intron 0 5 STAT3, CEBPB, EP300 MKL1 MCHR1
Table 1.  Overview of the prioritised SNP clusters in which at least one height and one post-menopausal breast 
or colorectal cancer risk-associated SNP were annotated to the same gene as based on either HapMap or GRAIL, 
complemented by the SNP-annotation to biological regulatory function information and gene-annotation to 
enriched pathway and gene ontology categories. Abbreviations: eQTL; expression quantitative trait loci; GWAS, 
genome-wide association study; LD, linkage disequilibrium NA, data not available in GWAS catalogue; SNP, single 
nucleotide polymorphism. aSNPs with the highest level of regulatory evidence were prioritised, indicated by the 
footnote (a). In cases were the regulatory evidence was equal, SNPs in high LD were prioritised according to the most 
significant p-value. bPhenotype specifies whether a SNP derived from the GWAS catalogues by Hindorff et al.14 and 
Johnson O’Donnel et al.15 is associated with height (H), breast cancer risk (BC) or colorectal cancer risk (CRC). cAn 
LD tag equal to one denotes two or more SNPs within the same cluster that are in high LD (r2 > 0.7). dRegulomeDB 
score for the putative regulatory function of a SNP. eGenes for which the SNP is a cis-eQTL according to 
RegulomeDB. (Cis-eQTLs are SNPs that are associated with mRNA expression of (a) nearby located gene(s)). fKnown 
transcription factor proteins that are binding to the genomic coordinates of the SNP according to RegulomeDB. gSNPs 
were annotated to a gene using the physical mapping of a SNP to a gene according to HapMap. hGene annotations 
using GRAIL (http://software.broadinstitute.org/mpg/grail/) were based on gene relationships among the complete 
set of SNPs listed in this table (S1 Table). In GRAIL, SNPs are annotated to genes by integrating the geographical 
location of a SNP derived from HapMap release 22with the biological data of a SNP obtained through text-mining 
using Pubmed 2014. GRAIL was set to correct for biases introduced by variable gene size when annotating the SNPs 
to genes. Large genes are more likely to have significant SNPs, and thus have a higher probability to be included in the 
regions that are being tested (Book: Computational Methods for Genetics of Complex Traits). iIndicated with check-
marks is whether the GRAIL gene annotation for a particular SNP contributed to the finding that the top three gene 
ontology terms, i.e. (#1) regulation of biosynthetic process (GO:009889), (#2) regulation of macromolecule metabolic 
process (GO:0060255), and (#3) epithelial cell proliferation (GO:0050673), were overrepresented in the total set of 
gene annotations from GRAIL (overrepresentation analyses were performed using ConsensusPathDB). jIndicates 
whether a gene mapped to a SNP is annotated to the overrepresented Indian hedgehog signalling pathway according 
to ConsensusPathDB.
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in cases and controls23 or SNPs related to the outcome24. The cocktail-method is an approach which combines 
features of two-step methods, the case-only design, and empirical Bayes techniques25. Still, these strategies inher-
ently lead to a higher probability of type I error, because SNPs are prioritised based on a genome-wide scan in 
the own study population without replication of the result. This can be avoided by selecting SNPs from publi-
cally available GWAS data, independent of the own study population, and using the clustering methodology to 
identify genomic regions of importance in relation to the phenotypes of interest. For most SNP clusters marking 
these regions, there is no particular expectation that the set of SNPs associated with the phenotypes of interest 
are themselves causal variants. Rather, the clusters mark regions in the human genome, which correlate with one 
or more causal variants. Therefore, the GWAS SNPs found in a single region likely tag similar mechanisms or 
causal variants and, in a way, may act as replication of the same result. These SNPs can then be taken forward to 
test for gene-environment interactions. The SNPs in the clusters may collectively point to pathways explaining 
the link between height and cancer risk. Previously, Mendelian randomization has been employed to make causal 
inferences regarding the link between height and colorectal cancer risk utilising genetic variants as a proxy for 
height. For example, Thrift et al.26 suggested a causal association between height-increasing alleles and a higher 
colorectal cancer risk in women, but further investigation was warranted in men26. An additional advantage of the 
clustering approach is that it is also particularly suitable for the investigation of several SNPs at once, all within 
one cluster, e.g. through the use of a genetic risk score, thereby accounting for multiple SNP effects and reducing 
the multiple testing problem.
Our SNP selection approach may also have some limitations. For example, the size of the genomic sliding win-
dow affected the cluster size and the number of clusters identified. Also, the method is reliant on published GWAS 
data which are not freely available at p-values ≥ 1 × 10−5 in the NHGRI GWAS Catalog and p-values > 1 × 10−3 in 
the Johnson and O’Donnell database. Furthermore, the number of SNPs from GWAS on height is relatively high 
compared to the number of SNPs from GWAS on breast and colorectal cancer risk; this might have to do with 
the fact that anthropometric data such as height is available in most studies. Nevertheless, the observation that a 
number of pathways of relevance to both height, post-menopausal breast cancer risk, and colorectal cancer risk 
were found overrepresented among the genes annotated to the SNPs in the clusters suggests that this approach 
can reveal biologically relevant information.
The notion that specific genes27,28 and genetic variants26,29,30 may be relevant for explaining the height-cancer 
association has been suggested previously. Our systematic SNP selection strategy showed the Ihh signalling path-
way to be overrepresented as based on variants that lie in/near BMP2, IHH, PTCH1, and STK36, when bas-
ing gene annotations on GRAIL. Cross-talks have been suggested between the Ihh signalling pathway and the 
Transforming Growth Factor-beta (TGF-β ) signalling pathway, which was found in overrepresentation analyses 
using HapMap gene annotations. Both pathways are of relevance to processes in growth plate regulation and the 
Pathways Set size
Number of 
genes from set in 
annotated gene list Genes p-value q-valueb Pathway source
Overrepresented pathways using the genes annotated to the prioritised set of SNPs associated with height, post-menopausal breast and colorectal cancer risk.
 Hedgehog signalling pathway 52 4 BMP2, STK36, IHH, PTCH1 7.78 × 10−7 2.08 × 10−5 KEGG
 Hedgehog signalling pathway 16 3 STK36, IHH, PTCH1 1.49 × 10−6 2.08 × 10−5 Wikipathways
 Hedgehog 25 3 STK36, IHH, PTCH1 6.06 × 10−6 5.56 × 10−5 NetPath
 Ligand-receptor interactions 8 2 IHH, PTCH1 5.76 × 10−5 3.77 × 10−4 Reactome
 Basal cell carcinoma 55 3 BMP2, STK36, PTCH1 6.73 × 10−5 1.63 × 10−3 KEGG
 HH-Core 19 2 IHH, PTCH1 3.48 × 10−4 1.63 × 10−3 Signalink
 Signalling events mediated by the Hedgehog family 23 2 IHH, PTCH1 5.14 × 10−4 2.06 × 10−3 PID
 Hedgehog, on, state 42 2 IHH, PTCH1 1.41 × 10−3 4.93 × 10−3 Reactome
 Hedgehog signalling events mediated by Gli proteins 50 2 STK36, PTCH1 2.24 × 10−3 6.97 × 10−3 PID
 Endochondral ossification 64 2 IHH, PTCH1 3.83 × 10−3 1.07 × 10−3 Wikipathways
 TGF-beta signalling pathway 80 2 BMP2, ID4 5.96 × 10−3 1.48 × 10−3 KEGG
 Signalling by Hedgehog 87 2 IHH, PTCH1 6.41 × 10−3 1.48 × 10−3 Reactome
 Class B/2 (Secretin family receptors) 88 2 IHH, PTCH1 6.87 × 10−3 1.48 × 10−3 Reactome
Overrepresented pathways using the genes annotated to the prioritised SNPs associated with height and post-menopausal breast cancer risk.
 Hedgehog signalling pathway 16 2 STK36, IHH 1.13 × 10−4 1.35 × 10−3 Wikipathways
 Hedgehog 25 2 STK36, IHH 2.81 × 10−4 1.68 × 10−3 NetPath
 Hedgehog signalling pathway 52 2 STK36, IHH 1.18 × 10−3 4.70 × 10−3 KEGG
 Signalling by ERBB4 153 2 ESR1, TNRC6B 9.02 × 10−3 2.19 × 10−2 Reactome
 Androgen receptor 149 2 ESR1, ZMIZ1 9.14 × 10−3 2.19 × 10−2 NetPath
Overrepresented pathways using the genes annotated to the prioritised SNPs associated with height and colorectal cancer risk.
 Hedgehog signalling pathway 52 2 BMP2, PTCH1 2.81 × 10−4 6.34 × 10−4 KEGG
 Basal cell carcinoma 55 2 BMP2, PTCH1 2.53 × 10−4 6.34 × 10−4 KEGG
Table 2.  Overrepresented pathways in prioritised SNP selectiona. Abbreviations: SNP, single nucleotide 
polymorphism. aOverrepresented pathways were retrieved using the SNP-gene annotations from GRAIL. bThe 
p-values are corrected for multiple testing using the false discovery rate method and are shown as q-values.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:41034 | DOI: 10.1038/srep41034
length of bones31,32 as well as tumour development33,34. Few hypothesis-based candidate-gene studies have been 
performed on SNPs in Ihh signalling pathway genes and breast or colorectal cancer risk. SNPs in TGF-β signal-
ling pathway genes have been associated with increased breast cancer risk35. Moreover, it has been found that a 
high number of at-risk variants in genes in the TGF-β signalling pathway increased the risk of colon and rectal 
cancer36. That cross-talks between Ihh and TGF-β signalling pathways are important in linking height to cancer, 
is likely when considering other complex diseases such as coronary artery disease (CAD). Consistent with an 
inverse association between height and CAD, a recent study showed that genetically determined height, as based 
on 180 height-associated SNPs from the Genetic Investigation of Anthropometric Traits (GIANT) consortium 
(which were not found in GWAS on CAD), was inversely associated with CAD, possibly via BMP/TGF-β signal-
ling37. Furthermore, interestingly, the basal cell carcinoma pathway is also significantly overrepresented in our 
results, which supports the previously reported height-basal cell cancer association38.
A number of SNPs were annotated to genes that fall in unanticipated pathways. Even though these pathways 
were not identified in our pathway overrepresentation analysis, these SNPs may provide new clues about the 
mechanisms that influence growth in relation to adult-attained height and breast and colorectal cancer risk. For 
example, of interest may be the melanin-concentrating hormone receptor (MCHR1) gene, to which both height- 
and breast cancer risk-associated SNPs were annotated. Several studies have supported a role for MCHR1 in the 
regulation of food consumption behaviour, energy expenditure and body weight39,40. Previously, a cross-sectional 
study found that polymorphisms in the MCHR1 gene were associated with differences in body composition and 
interacted with energy-related lifestyle factors41. Body fatness is, next to adult-attained height, a convincing risk 
factor for post-menopausal breast cancer7. Therefore, nutrient-sensing processes might be a common mechanism 
linking height and other anthropometric factors to breast cancer risk.
Unexpectedly, no clusters were identified that contained SNPs that were associated with all three phenotypes, 
i.e. height, post-menopausal breast cancer risk, and colorectal cancer risk. This might be explained by the fact that 
the p-value cut-off (p-value = 1 × 10−5) used for GWAS SNPs, although liberal, was not sufficiently liberal to find 
clusters that represented all three phenotypes. Likely, at even more liberal p-values, there is a higher probability 
of finding a shared component to complex traits, such as height and the risk of cancer, which may be involving 
thousands of common alleles with rather small effects42. Our results suggest that, in addition to a shared com-
ponent, there may also be different mechanisms through which height influences post-menopausal breast and 
colorectal cancer risk. The mechanisms identified linking height to colorectal cancer risk overlapped with those 
found in overall pathway overrepresentation analyses in this study and these may operate primarily through 
Ihh signalling. The mechanisms linking height to post-menopausal breast cancer risk may go through Ihh sig-
nalling as well as ERBB4 signalling and androgen receptor signalling. Both ERBB4 signalling43,44 and andro-
gen receptor signalling45,46 are involved in mammary gland development. Future studies can utilise the SNPs 
in height-post-menopausal breast and height-colorectal cancer clusters to conduct mediation analyses between 
SNPs and specific cancer endpoints with height as a mediating factor or to perform interaction analyses between 
SNPs and height with specific cancer endpoints.
Finally, it is only fair to mention that our method is likely to pick up some degree of pleiotropic effects in terms 
of SNP effects or gene effects, especially considering our prioritisation step in which we prioritised clusters with 
at least one height- and one cancer risk-associated SNP. In this report, however, we focused on the instrumental 
value of the clusters in terms of future gene-environment interaction analyses or mediation analyses aimed at 
elucidating disease aetiology, rather than on trying to pinpoint pleiotropic SNPs or genes. Nevertheless, it is good 
GO termsa Set size
Number of 
genes from set in 
annotated gene list p-value q-valueb
Sub-analysis: 





GO:0009889 regulation of biosynthetic 
process 4061 15 4.85 × 10
−6 6.21 × 10−4 ✓
GO:0060255 regulation of 
macromolecule metabolic process 5358 16 2.85 × 10
−5 1.80 × 10−3 ✓
GO:0050673 epithelial cell proliferation 323 5 3.29 × 10−5 3.30 × 10−2 ✓ ✓
GO:0048754 branching morphogenesis 
of an epithelial tube 170 4 4.55 × 10
−5 1.80 × 10−3 ✓ ✓
GO:0090304 nucleic acid metabolic 
process 4893 15 5.61 × 10
−5 1.80 × 10−3 ✓
GO:0016070 RNA metabolic process 4339 14 7.48 × 10−5 1.81 × 10−3 ✓
GO:0061138 morphogenesis of a 
branching epithelium 202 4 8.47 × 10
−5 1.81 × 10−3 ✓
GO:0048732 gland development 407 5 9.38 × 10−5 3.30 × 10−3 ✓ ✓
GO:0060322 head development 678 6 10.40 × 10−4 3.30 × 10−3 ✓
GO:0001763 morphogenesis of a 
branching structure 213 4 10.50 × 10
−4 3.30 × 10−3 ✓
Table 3.  Top ten most significantly overrepresented gene-ontology terms in prioritised SNP selectiona. 
Abbreviations GO, gene ontology; SNP, single nucleotide polymorphism. aOverrepresentation analysis for GO 
terms were performed using using the SNP-gene annotations from GRAIL. bThe p-values are corrected for 
multiple testing using the false discovery rate method and are available as q-values. cThe check-mark indicates 
which of the top 10 GO-terms from the main GO overrepresentation analysis were also present in separate 
analyses for breast and colorectal cancer risk.
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to realise that several other methods exist that are aimed at identifying potential pleiotropic effects47–49. These 
methods may, in part, confirm the results at hand, when applied to the same topic. However, due to differences in 
input and methodology, it is likely that also different signals will be picked up. It is beyond the scope of this paper 
to identify all existing methods and validate these against each other, but we encourage future efforts in relation 
to this issue. Such efforts preferably need to include the use of simulated data in order to be able to draw conclu-
sions about the extent to which different signals are picked up by different methods and about the extent to which 
different methods can distinguish between true signals and noise.
Conclusion
We report a novel SNP selection approach to systematically restrict the number of SNPs for genotyping in 
large-scale studies aimed at elucidating aetiologic pathways. Our approach is of particular interest for stud-
ies with exhaustive bio-samples, in which a genome-wide approach is not feasible, and will reduce the costs 
of genotyping and the chance of false-positive findings. The SNPs identified can be used to, for example, study 
gene-environment interactions or to conduct mediation analyses. The novelty of this method is the comprehen-
sive integration of publically available GWAS repositories on the basis of which SNPs associated with multiple 
linked complex traits and diseases can be identified as these are hypothesised to cluster in regions of low recombi-
nation. Such SNPs may serve as time-independent biomarkers of pathway involvement to mechanistically under-
pin established associations. Of interest in this paper was the association between adult-attained height and the 
risk of post-menopausal breast and colorectal cancer, for which the Ihh signalling pathway was found to be poten-
tially important. This pathway was also found in separate analyses for height-post-menopausal breast cancer and 
height-colorectal cancer clusters, but there may also be different biological mechanisms through which height is 
associated with post-menopausal breast as compared to colorectal cancer risk.
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